Filing Details

Accession Number:
0001415889-22-004708
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-06 16:30:33
Reporting Period:
2022-05-05
Accepted Time:
2022-05-06 16:30:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1082554 United Therapeutics Corp UTHR Pharmaceutical Preparations (2834) 521984749
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1231589 A Paul Mahon C/O United Therapeutics Corporation
1040 Spring Street
Silver Spring MD 20910
Evp & General Counsel No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-05-05 6,000 $111.00 42,397 No 4 M Direct
Common Stock Disposition 2022-05-05 1,300 $189.38 41,097 No 4 S Direct
Common Stock Disposition 2022-05-05 3,100 $190.36 37,997 No 4 S Direct
Common Stock Disposition 2022-05-05 900 $191.72 37,097 No 4 S Direct
Common Stock Disposition 2022-05-05 700 $192.92 36,397 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options Disposition 2022-05-05 6,000 $0.00 6,000 $111.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,552 2021-03-15 2028-03-15 No 4 M Direct
Footnotes
  1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
  2. This transaction was executed in multiple trades at prices ranging from $188.955 to $189.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $190.085 to $190.955. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $191.315 to $191.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This transaction was executed in multiple trades at prices ranging from $192.50 to $193.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021.